H.C. Wainwright analyst lowers Kala Pharmaceuticals' price target

May 24, 2022 10:18 AM ETKALABy: Mary Christine Joy, SA News Editor3 Comments
  • Kala Pharmaceuticals (KALA) lost ~20% of its value after H.C. Wainwright Analyst Yi Chen lowered the company's price target to $4 from $5.
  • The analyst maintained a Buy rating on the shares.
  • The move comes after KALA entered into a definitive pact to sell its commercial portfolio and related intellectual property assets to Alcon.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.